# The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)

> **NCT04517227** · NA · UNKNOWN · sponsor: **Fudan University** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Durvalumab
- **PROCEDURE:** Transcatheter Hepatic Arterial Chemoembolization (TACE)
- **PROCEDURE:** Ablation

## Key facts

- **NCT ID:** NCT04517227
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07
- **Primary completion:** 2025-06
- **Final completion:** 2025-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04517227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04517227, "The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04517227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*